Top of this page
Skip navigation, go straight to the content
Scroll down to discover UCB
EVENITY® (Romosozumab)
| Disease area studied |
Abbreviated title | Phase | Study ID | Registry database | Study results | Plain language summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Osteoporosis |
A study to learn how romosozumab worked in men with osteoporosis |
20110174 Completed |
LINK |
Lewiecki et al., Journal of clinical endocrinology and metabolism 2018; 103(9):3183–93 | |||
| Osteoporosis | A study to learn how romosozumab worked in women with osteoporosis who had gone through menopause |
20110142 Completed |
LINK |
Brown, J Bone Miner Res 2021 epub Cosman, J Bone Miner Res 2020; 35(7):1333–42 | |||
| Osteoporosis | A study to learn how romosozumab worked in women with osteoporosis who had gone through menopause |
20070337 Completed |
|
LINK |
Cosman, N Engl J Med 2016; 375(16):1532–43 Cosman, Journal of bone and mineral research 2018; 33(7):1219–26 Cosman, J Bone Miner Res 2018; 33(8):1407–16 Lewiecki EM, J Bone Miner Res 2019; 34(3):419–28 McCloskey, Osteoporos Int 2021; 32(8):1601-1608 Miyauchi, Arch Osteoporos 2019; 14(1):59 Chavassieux, Journal of bone and mineral research 2019; 34(9):1597–608 Miyauchi Journal of bone and mineral metabolism 2021; 39(2):278–88 |
||
Osteoporosis postmenopausal |
European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance |
OP0004 Ongoing |
EUPAS35881 | ||||
| Osteoporosis postmenopausal | European non-interventional post-authorization safety study related to adherence to the risk minimization measures for romosozumab by the EU-ADR Alliance |
OP0005 Ongoing |
EUPAS35956 | ||||
| Osteoporosis postmenopausal | European non-interventional post-authorization safety study related to serious infections for romosozumab by the EU-ADR Alliance |
OP0006 Ongoing |
EUPAS36005 |
|